Helicobacter pylori infection: physiopathologic implication of N alpha-methyl histamine.

Centre hospitalier de Villeneuve-Saint-Georges, Villeneuve, Île-de-France, France
Gastroenterology (Impact Factor: 13.93). 05/1995; 108(4):959-66. DOI: 10.1016/0016-5085(95)90190-6
Source: PubMed

ABSTRACT In the gastric mucosa of Helicobacter pylori-infected subjects, we previously detected N alpha-methyl histamine (N alpha-MeHA), a minor catabolite of histamine and a potent agonist of histamine H3 receptors. The origin of N alpha-MeHA and its effects on gastric histamine and somatostatin in infected subjects were investigated.
Ten noninfected patients and 13 patients with intense colonization were compared. N alpha-MeHA content and its synthetic enzyme activity, N alpha-histamine methyltransferase, binding of [3H]N alpha-MeHA, histamine and somatostatin contents, and histidine decarboxylase activity were assayed in antral and fundic biopsy specimens and in cultured H. pylori strains.
Gastric histamine and somatostatin contents as well as histidine decarboxylase activity were decreased in infected patients and were restored to normal after antimicrobial treatment. Both N alpha-MeHA and N alpha-histamine methyltransferase activity were present in the mucosa of infected patients and in cultured strains and were very low in noninfected patients or after eradication of H. pylori. [3H]N alpha-MeHA bound to gastric mucosa but not to cultured strains. The [3H]N alpha-MeHA specific binding sites were characterized as H3 receptors. The amount of bound [3H]N alpha-MeHA seemed correlated positively with somatostatin content and histidine decarboxylase activity and negatively with N alpha-MeHA content and N alpha-histamine methyltransferase activity.
H. pylori is the main source of gastric N alpha-MeHA that may lower histidine decarboxylase activity and somatostatin content through H3 receptors.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori (H. pylori) have long been associated with a spectrum of disease outcomes in the gastro-duodenal system. Heterogeneity in bacterial virulence factors or strains is not enough to explain the divergent disease phenotypes manifested by the infection. This review focuses on host genetic factors that are involved during infection and eventually are thought to influence the disease phenotype. We have summarized the different host genes that have been investigated for association studies in H. pylori mediated duodenal ulcer or gastric cancer. We discuss that as the bacteria co-evolved with the host; these host gene also show much variation across different ethnic population. We illustrate the allelic distribution of interleukin-1B, across different population which is one of the most popular candidate gene studied with respect to H. pylori infections. Further, we highlight that several polymorphisms in the pathway gene can by itself or collectively affect the acid secretion pathway axis (gastrin: somatostatin) thereby resulting in a spectrum of disease phenotype.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radioligand binding experiments carried out in cell membranes from rat and human stomach revealed the existence of non-adrenoceptor [3H]clonidine and [3H]idazoxan binding sites and of [3H]DTG (1,2-di-(2-tolyl)guanidine) binding sites. In rat stomach, specific binding was inhibited by imidazolines and guanidines and by non-imidazoline σ-site ligands, respectively, at different rank orders of affinity, suggesting the existence of non-I1/non-I2 [3H]clonidine binding sites, I2-imidazoline binding sites as well as σ2-like-sites. These sites are not directly related to a postsynaptic contractile effect on rat gastric smooth muscle or to acid release from isolated gastric glands. Finally, we demonstrated that the gastric pathogen Helicobacter pylori is able to form and to release the endogenous imidazoline receptor ligand agmatine and that considerable amounts of agmatine are present in human gastric juice. The quantities of agmatine were higher in gastric juice from H. pylori-positive than H. pylori-negative patients.
    Annals of the New York Academy of Sciences 02/2006; 881(1):332 - 343. DOI:10.1111/j.1749-6632.1999.tb09377.x · 4.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & Aims: Enterochromaffin-like (ECL) cells are histamine-containing endocrine cells in the gastric mucosa. Previous studies have shown that the proinflammatory cytokine interleukin (IL)-1β present during chronic gastritis inhibits histamine synthesis in ECL cells and leads to sustained functional impairment. This study investigated the effects of IL-1β on ECL cell apoptosis and the related signal-transduction mechanisms. Methods: ECL cells were isolated by pronase digestion and a combination of elutriation, gradient centrifugation, and 48-hour culture (purity ≥90%). Apoptosis was measured by terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling reaction and cell death detection enzyme-linked immunosorbent assay. Results: IL-1β (100 pg/mL) increased the rate of programmed cell death 2–3 fold in ECL cells after 24 hours of incubation (total of 12%–14%). This effect was completely inhibited by the NF-κB inhibitor, proteasome inhibitor I, and the nitric oxide synthase inhibitor (iNOS) NG-monomethyl-L-arginine (10−4 mol/L), but not by the caspase 3 inhibitor, Asp-Glu-Val-Asp-CHO. Western blot analysis, reverse-transcription polymerase chain reaction (PCR), and in situ PCR showed that IL-1β induced gene expression (after 2–4 hours) and protein synthesis (6–18 hours) of the iNOS isoform in ECL cells. Bax protein expression was increased in response to IL-1β. In contrast, bcl-2 gene expression was increased in response to basic fibroblast growth factor, which has been shown to counteract IL-1β– induced apoptosis. Conclusions: These data suggest that IL-1β induces programmed cell death in isolated rat ECL cells via activation of NF-κB, iNOS, and the Bax protein.GASTROENTEROLOGY 2000;118:515-524
    Gastroenterology 03/2000; 118(3):515-524. DOI:10.1016/S0016-5085(00)70257-5 · 13.93 Impact Factor


Available from
May 30, 2014